O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150

医学 索拉非尼 阿替唑单抗 内科学 贝伐单抗 肝细胞癌 肿瘤科 总体生存率 生活质量(医疗保健) 无进展生存期 扩展访问 不利影响 伦瓦提尼 胃肠病学 癌症 化疗 无容量 免疫疗法 护理部
作者
D. Li,Han Chong Toh,Philippe Merle,Kaoru Tsuchiya,Sairy Hernandez,Hui Shao,Sohail Mulla,Beiying Ding,Masatoshi Kudo
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:31: 234-234 被引量:11
标识
DOI:10.1016/j.annonc.2020.04.061
摘要

Data regarding the efficacy and safety of systemic therapies in older adults with hepatocellular carcinoma (HCC) are limited. In the phase III IMbrave150 trial, atezolizumab + bevacizumab was associated with statistically significant and clinically meaningful improvements in overall survival (OS; HR, 0.58; 95% CI: 0.42, 0.79) and progression-free survival (PFS; HR, 0.59; 95% CI: 0.47, 0.76) as well as clinically meaningful delays in deterioration of patient-reported functioning and quality of life (QoL) vs sorafenib in patients with unresectable HCC who had not received prior systemic therapy (Cheng, ESMO Asia, 2019). Here, we report exploratory subgroup analyses of the efficacy, safety and patient-reported outcome (PRO) results for older adults enrolled in IMbrave150. IMbrave150 randomized 501 systemic treatment (tx)–naïve patients with unresectable HCC. Patients were randomized 2:1 to receive either atezolizumab 1200 mg IV q3w + bevacizumab 15 mg/kg IV q3w or sorafenib 400 mg BID until unacceptable toxicity or loss of clinical benefit per investigator. Co-primary endpoints were OS and PFS by independent review facility (IRF)-assessed RECIST 1.1. Objective response rate (ORR) per IRF-RECIST 1.1 and time to deterioration (TTD) in patient-reported physical functioning, role functioning and QoL per the EORTC QLQ-C30 questionnaire were pre-specified secondary endpoints. The exploratory older adult subgroup was defined to include those aged ≥ 65 years. In IMbrave150, 161 (48%) patients enrolled in the atezolizumab + bevacizumab arm and 91 (55%) in the sorafenib arm were aged ≥ 65 years. In these patients, the median OS was not reached with atezolizumab + bevacizumab vs 14.9 months with sorafenib (HR, 0.58; 95% CI: 0.36, 0.92). The median PFS was 7.7 months with atezolizumab + bevacizumab vs 4.8 months with sorafenib (HR, 0.63; 95% CI: 0.45, 0.89). ORRs were 26% with atezolizumab + bevacizumab vs 13% with sorafenib, with 7 and 0 patients achieving complete responses, respectively. TTD in physical functioning (HR, 0.48; 95% CI: 0.32, 0.73), role functioning (HR, 0.61; 95% CI: 0.40, 0.91) and QoL (HR, 0.71; 95% CI: 0.47, 1.07) were longer for patients receiving atezolizumab + bevacizumab vs sorafenib. In the atezolizumab + bevacizumab arm, 62 of 158 (39%) treated patients aged ≥ 65 years experienced a grade 3-4 treatment-related AE (TRAE) and 4 (3%) patients experienced a grade 5 TRAE, whereas 55 of 171 (32%) treated patients aged < 65 years experienced a grade 3-4 TRAE and 1 (1%) patient experienced a grade 5 TRAE. Exploratory analyses were also conducted with the subgroup of patients aged ≥ 70 years, showing similar results for efficacy, safety and PROs. Similar to the IMbrave150 ITT population, older adults with previously untreated, unresectable HCC derived a clinically meaningful benefit from atezolizumab + bevacizumab vs sorafenib. Additionally, treatment with atezolizumab + bevacizumab showed a delay in deterioration in patient-reported functioning and QoL vs sorafenib. Safety of atezolizumab + bevacizumab in adults ≥ 65 years old is generally consistent with the safety in younger patients, with no added risks or toxicities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
7秒前
风趣问雁完成签到 ,获得积分10
8秒前
8秒前
9秒前
111111zx111发布了新的文献求助10
12秒前
13秒前
温柔季节发布了新的文献求助10
14秒前
song完成签到 ,获得积分10
14秒前
qqq发布了新的文献求助10
14秒前
15秒前
15秒前
JamesPei应助王武聪采纳,获得10
16秒前
Rondab应助失眠的狗采纳,获得10
18秒前
19秒前
19秒前
wkjfh完成签到,获得积分0
20秒前
唐卟哩钵完成签到,获得积分10
20秒前
Rondab应助hg08采纳,获得10
21秒前
拓跋凝海完成签到,获得积分10
21秒前
21秒前
23秒前
24秒前
沉默的宛筠应助liu采纳,获得10
24秒前
Transition发布了新的文献求助10
25秒前
家家完成签到 ,获得积分10
25秒前
默默的如凡完成签到,获得积分10
25秒前
26秒前
ioio发布了新的文献求助10
26秒前
qqq完成签到,获得积分10
28秒前
29秒前
天天快乐应助Amon采纳,获得10
30秒前
32秒前
34秒前
包李发布了新的文献求助10
36秒前
111111zx111完成签到,获得积分10
37秒前
精美礼物给精美礼物的求助进行了留言
38秒前
NexusExplorer应助raolixiang采纳,获得10
40秒前
40秒前
哲别发布了新的文献求助10
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989797
求助须知:如何正确求助?哪些是违规求助? 3531914
关于积分的说明 11255516
捐赠科研通 3270597
什么是DOI,文献DOI怎么找? 1805008
邀请新用户注册赠送积分活动 882181
科研通“疑难数据库(出版商)”最低求助积分说明 809190